Tag: Jeff Emmick
Lilly’s Zepbound marks remarkable weight loss milestone in SURMOUNT-4 study
In a significant development in the field of obesity treatment, Lilly's Zepbound (tirzepatide) has shown remarkable results in the SURMOUNT-4 study. Published in The Journal ... Read More
Eli Lilly’s Tirzepatide triumphs in Phase 3 weight loss studies
Eli Lilly and Company has unveiled the results of two Phase 3 tirzepatide studies (SURMOUNT-3 and SURMOUNT-4) targeting adults with obesity or overweight with weight-related ... Read More